Utilization of hepatocellular carcinoma surveillance programs in patients with cirrhosis: A systematic review and meta-analaysis.

Authors

null

Jameel Kenneth Singh

Zucker School of Medicine/Northwell Health at Mather, Port Jefferson, NY

Jameel Kenneth Singh , Daryl Ramai , Nicola Tartaglia , Antonio Ambrosi , Shahab R. Khan , Saurabh Chandan , Antonio Facciorusso

Organizations

Zucker School of Medicine/Northwell Health at Mather, Port Jefferson, NY, The Brooklyn Hospital Center, Brooklyn, NY, University of Foggia, Foggia, Italy, Brigham and Women's Hospital, Harvard Medical School, Department of Medicine, Boston, MA, CHI Health Creighton University Medical Center, Omaha, NE, Universita degli Studi di Bari, Bari, Italy

Research Funding

No funding received
None

Background: Patients with cirrhosis are advised to undergo hepatocellular carcinoma (HCC) surveillance every six months. Routine screening is associated with early tumor detection and improved survival. However, surveillance is underutilized. We aimed to characterize the impact of HCC surveillance interventions on patient uptake and concomitant detection of HCC. Methods: We performed a comprehensive literature search of major databases (from inception to October 2020) to identify studies which assess the impact of HCC surveillance programs in patients with cirrhosis. Our primary endpoint was uptake of screening defined as having an abdominal sonogram every at least every 6 months. Secondary endpoint was the detection of HCC following screening. Pooled data was assessed using a random-effects model expressed in terms of odds ratio (OR) and 95% confidence interval (CI). Results: Nine studies were included for meta-analysis which involved 5,021 patients with cirrhosis. Patients with a history of hepatitis B or C accounted for 40.5% of the study cohort. Comparing both screening and control groups, patients were 5 times more likely to undergo abdominal sonography if they participated in surveillance programs versus usual care (OR 4.69; CI: 2.41 – 9.13, I2: 94%). Overall, the mean difference in patients who did undergo screening versus those who did not participate in surveillance was 30.6% (CI: 19.2% – 41.9%, P < 0.001). Comparing both screening and control groups, patients were 1.5 times more likely to be diagnosed with HCC if they participated in surveillance programs (OR 1.49; CI: 0.57 – 3.89, I2: 65%). On subgroup analysis, comparing type of intervention program, dedicated surveillance programs showed a higher uptake compared to clinical reminders, though not statistically significant (dedicated programs OR 62.6, CI: 1.53 – 2559.5 vs clinical reminders OR 2.63, CI: 1.82 – 3.79). Conclusions: Patient uptake in HCC surveillance remains underutilized. Interventions such as dedicated surveillance programs and clinical reminders systems can significantly increase uptake of abdominal sonography and cancer detection.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2021 ASCO Annual Meeting

Session Type

Publication Only

Session Title

Publication Only: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr e16141)

DOI

10.1200/JCO.2021.39.15_suppl.e16141

Abstract #

e16141

Abstract Disclosures

Similar Abstracts

First Author: Vedaamrutha Reddy

Abstract

2022 ASCO Gastrointestinal Cancers Symposium

Provider- and system-level barriers to surveillance for hepatocellular carcinoma among patients with chronic liver disease.

First Author: Eliza W. Beal

First Author: Jagpreet Chhatwal

Abstract

2024 ASCO Annual Meeting

Effect of malnutrition on cirrhotic patients with hepatocellular carcinoma: A nationwide study.

First Author: Adham Obeidat